The 2022 OncoAlert Colloquium Day 1: Breast Cancer

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer

HER-Vaxx is safe and provides clinical benefit over standard of care chemo for patients with HER2-overexpressing gastric cancer

Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and OS in CLDN18.2+/ HER2 mG/GEJ adenocarcinoma

Kinetics of postop circulating cell-free DNA and impact on MRD detection rates in resected stage I-III colorectal cancer

OPERA: Nonoperative modality (NOM) treatments of rectal cancer do not compromise the chance of cure

NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful survival benefit vs chemo for advanced ESCC

The placebo effect in oncology trials and the criteria for approving drugs

Breast-conserving therapy may be option for multiple breast lesions

ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL

Shorter time from leukapheresis to infusion of axi-cel corresponds to better CR and OS in r/r LBCL patients

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1